Sanofi (NEO:SAN)
Canada · Delayed Price · Currency is CAD | Market Cap | 144.69B -12.7% |
| Revenue (ttm) | 76.21B +4.8% |
| Net Income | 12.16B +19.9% |
| EPS | 9.98 +23.0% |
| Shares Out | n/a |
| PE Ratio | 11.90 |
| Forward PE | 8.61 |
| Dividend | 0.86 (9.00%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 200 |
| Open | 9.55 |
| Previous Close | 9.57 |
| Day's Range | 9.55 - 9.55 |
| 52-Week Range | 9.20 - 11.60 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsNews
Sanofi's Sarclisa Subcutaneous Combination Therapy Gets Japan Approval For Multiple Myeloma
(RTTNews) - French drug major Sanofi (SNY, SAN.PA) announced Friday that Sarclisa (isatuximab) subcutaneous (SC) formulation combination therapy has been approved in Japan for patients with multiple m...
Sanofi: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated no...
Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-i...
Sanofi SA (SNY) Stock Down 3.5% -- Now Undervalued? GF Score: 73/100
Sanofi SA (SNY) Stock Down 3.5% -- Now Undervalued? GF Score: 73/100
Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sanofi (SNY) to EUR 95 from EUR 100 and keeps a Buy rating on the shares.
Sanofi: Information concerning the total number of voting rights and shares – May 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Sanofi (SNY) Gains FDA Approval for Expanded Use of Tzield in Type 1 Diabetes
Sanofi (SNY) Gains FDA Approval for Expanded Use of Tzield in Type 1 Diabetes
FDA Grants Accelerated Approval To Sanofi's Tzield For Children With Stage 3 Type 1 Diabetes
(RTTNews) - Sanofi (SNY) announced that the U.S. Food and Drug Administration has granted accelerated approval to Tzield (teplizumab-mzwv) for delaying the decline in endogenous insulin production in ...
Sanofi: Sanofi's Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi's Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes Accelerated approval in children aged eight to 17 years old re...
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
The U.S. Food and Drug Administration approved Sanofi's injection to slow the loss of the body's own insulin production in children aged 8 to 17 years recently diagnosed with stage 3 typ...
Strong Buy Rating on Sanofi (SNY) Following Positive Study Results
Strong Buy Rating on Sanofi (SNY) Following Positive Study Results
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move ...
Sanofi (SNY) Halts Study, Analyst Says Dianthus Selloff Overstated
Sanofi (SNY) Halts Study, Analyst Says Dianthus Selloff Overstated
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright
After Sanofi (SNY) announced that it is stopping the pivotal MOBILIZE study evaluating riliprubart in chronic inflammatory demyelinating polyneuropathy patients refractory to standard of care based on...
Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics
Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics
Dianthus Therapeutics (DNTH) Shares Drop Over 20% Following Sanofi Trial Halt
Dianthus Therapeutics (DNTH) Shares Drop Over 20% Following Sanofi Trial Halt
Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus
Stifel notes that Sanofi (SNY) announced this morning that they are discontinuing the MOBILIZE Phase 3 study of riliprubart in CIDP patients refractory to IVIg based on an IDMC interim…
Dianthus sinks after Sanofi halts CIDP Phase 3 study
Shares of Dianthus Therapeutics (DNTH) after sinking after Sanofi (SNY) announced that its riliprubart Phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy will be stopped....
Sanofi (SNY) Halts Phase 3 Study on CIDP Treatment
Sanofi (SNY) Halts Phase 3 Study on CIDP Treatment
Sanofi to halt riliprubart Mobilize phase 3 study
Sanofi (SNY) announced that the riliprubart Mobilize phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy, CIDP, refractory to standard-of-care treatment will be stopped. T...
Sanofi (SNY) Halts Phase 3 Trial of Riliprubart Due to Efficacy Concerns
Sanofi (SNY) Halts Phase 3 Trial of Riliprubart Due to Efficacy Concerns
Sanofi Discontinues Phase 3 MOBILIZE Trial For Riliprubart In Treating CIDP
(RTTNews) - Sanofi (SNY), a biopharmaceutical company, on Wednesday announced the discontinuation of the Phase 3 MOBILIZE trial for Riliprubart in treating chronic inflammatory demyelinating polyneuro...
Sanofi ends Phase 3 riliprubart trial after weak interim results
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient...
Sanofi to Stop Late-Stage Study of Immune-Disorder Drug
The termination is an early setback to new chief executive Belen Garijo, who took the helm last month.